Successful treatment with rituximab for autoimmune hemolytic anemia concomitant with proliferation of Epstein-Barr virus and monoclonal gammopathy in a post-nonmyeloablative stem cell transplant patient

Annals of Hematology

Volumn 83, Issue 2, 2004, Pages 114-116

  Endo, T ^a   Nakao, S ^b   Koizumi, K ^a   Nishio, M ^a   Fujimoto, K ^a   Sakai, T ^a   Kumano, K ^a   Obara, M ^a   Koike, T ^a  

^a HOKKAIDO UNIVERSITY   (Japan)

^b KANAZAWA UNIV SCHOOL OF MEDICINE   (Japan)

Author keywords

Autoimmune hemolytic anemia (AIHA); EBV); Epstein Barr virus; Monoclonal gammopathy; Post transplant lymphoproliferative disorder (PTLD); Rituximab

Indexed keywords

ANTIBIOTIC AGENT; CYCLOSPORIN A; IMMUNOGLOBULIN; METHOTREXATE; PREDNISOLONE; RITUXIMAB; TACROLIMUS; VIRUS DNA;

ADULT; APLASTIC ANEMIA; ARTICLE; AUTOIMMUNE HEMOLYTIC ANEMIA; CASE REPORT; DOSE RESPONSE; EPSTEIN BARR VIRUS; FEMALE; GRAFT VERSUS HOST REACTION; HLA MATCHING; HUMAN; IMMUNOELECTROPHORESIS; IMMUNOSUPPRESSIVE TREATMENT; LYMPHOPROLIFERATIVE DISEASE; MONOCLONAL IMMUNOGLOBULINEMIA; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; PNEUMONIA; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SIDE EFFECT; TREATMENT OUTCOME; VIRUS INFECTION;

ADULT; ANEMIA, HEMOLYTIC, AUTOIMMUNE; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; DNA, VIRAL; EPSTEIN-BARR VIRUS INFECTIONS; FEMALE; HAPTOGLOBINS; HEMOGLOBINS; HUMANS; IMMUNOGLOBULINS; LEUKOCYTES, MONONUCLEAR; LYMPHOPROLIFERATIVE DISORDERS; MYELOABLATIVE AGONISTS; PARAPROTEINEMIAS; POSTOPERATIVE COMPLICATIONS; STEM CELL TRANSPLANTATION; TRANSPLANTATION CONDITIONING; TREATMENT OUTCOME;

EID: 0842308261     PISSN: 09395555     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00277-003-0740-z     Document Type: Article

References (15)

1. Badley AD, Portela DF, Patel R, Kyle RA, Habermann TM, Strickler JG, Ilstrup DM, Wiesner RH, Groen P, Walker RC, Paya CV (1996) Development of monoclonal gammopathy precedes the development of Epstein-Barr lymphoproliferative disorder. Liver Transpl Surg 2:375-382
2. Chen FE, Owen I, Savage D, Roberts I, Apperley J, Goldman JM, Laffan M (1997) Late onset haemolysis and red cell autoimmunisation after allogeneic bone marrow transplant. Bone Marrow Transplant 19:491-495
3. Drobyski WR, Potluri J, Sauer D, Gottschall JL (1996) Autoimmune hemolytic anemia following T cell-depleted allogeneic bone marrow transplantation. Bone Marrow Transplant 17:1093-1099
4. van Esser JW, Niesters HGM, van der Holt B, Meijer E, Osterhaus ADME, Gratama JW, Verdonck LF, Lowenberg B, Cornelissen JJ (2002) Prevention of Epstein-Barr virus-lymphoproliferative disease by molecular monitoring and preemptive rituximab in high-risk patients after allogeneic stem cell transplantation. Blood 99:4364-4369
5. Faye A, Quartier P, Reguerre Y, Lutz P, Carret AS, Dehee A, Rohrlich P, Peuchmaur M, Matthieu-Boue A, Fischer A, Vilmer E (2001) Chimeric anti-CD20 monoclonal antibody (rituximab) in post-transplant B-lymphoproliferative disorder following stem cell transplantation in children. Br J Haematol 115:112-118
6. Fischer A, Landais P, Friedrich W, Gerritsen B, Fasth A, Porta F, Vellodi A, Benkerrou M, Jais JP, Cavazzana-Calvo M, et al (1994) Bone marrow transplantation in Europe for primary immunodeficiencies other than severe combined immunodeficiency ESCT/EGID report. Blood 83:1149-1154
7. Hongeng S, Tardtong P, Worapongpaiboon S, Ungkanont A, Jootar S (2002) Successful treatment of refractory autoimmune haemolytic anaemia in a post-unrelated bone marrow transplant paediatric patient with rituximab. Bone Marrow Transplant 29:871-872
8. Horn B, Viele M, Mentzer W, Mogck N, DeSantes K, Cowan M (1999) Autoimmune hemolytic anemia in patients with SCID after T cell-depleted BM and PBSC transplantation. Bone Marrow Transplant 24:1009-1013
9. Nishio M, Nakao S, Endo T, Fujimoto K, Takashima H, Sakai T, Bacigalupo A, Koike T, Sawada K (2001) Successful nonmyeloablative stem cell transplantation for a heavily transfused woman with severe aplastic anemia complicated by heart failure. Bone Marrow Transplant 28:783-785
10. Paya CV, Fung JJ, Nalesnik MA, Kieff E, Green M, Gores G, Habermann TM, Wiesner PH, Swinnen JL, Woodle ES, Bromberg JS (1999) Epstein-Barr virus-induced post-transplant lymphoproliferative disorders. ASTS/ASTP EBV-PTLD Task Force and The Mayo Clinic Organized International Consensus Development Meeting. Transplantation 68:1517-1525
11. Shapiro RS, McClain K, Frizzera G, Gajl-Peczalska KJ, Kersey JH, Blazar BR, Arthur DC, Patton DF, Greenberg JS, Burke B, et al (1988) Epstein-Barr virus associated B cell lymphoproliferative disorders following bone marrow transplantation. Blood 71:1234-1243
12. Treon SP, Anderson KC (2000) The use of rituximab in the treatment of malignant and non malignant plasma cell disorders. Semin Oncol 27:79-85
13. Verschuuren EA, Stevens SJ, van Imhoff GW, Middeldorp JM, de Boer C, Koeter G, The TH, van Der Bij W (2002) Treatment of posttransplant lymphoproliferative disease with rituximab: the remission, the relapse, and the complication. Transplantation 73:100-104
14. Zecca M, De Stefano P, Nobili B, Locatelli F (2001) Anti-CD20 monoclonal antibody for the treatment of severe, immunemediated pure red cell aplasia and hemolytic anemia. Blood 97:3995-3997
15. Zutter MM, Martin PJ, Sale GE, Shulman HM, Fisher L, Thomas ED, Durnam DM (1988) Epstein-Barr virus lymphoproliferation after bone marrow transplantation. Blood 72:520-529